{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:27:06Z","timestamp":1760059626822,"version":"build-2065373602"},"reference-count":74,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Autoimmune hepatitis (AIH) is the most common liver disease caused by autoimmunity. In Japan, the number of patients with AIH has been increasing in recent years. AIH develops as a result of the loss of immune tolerance to autoantigens in the liver. Drug-induced liver injury (DILI) is an extremely important cause of liver injury in clinical practice and should always be kept in mind in the differential diagnosis. Recently, DILI caused by immune checkpoint inhibitors has been attracting attention. For the diagnosis of DILI, it is important to carefully exclude other possible causes of liver injury and obtain a detailed history of medications and the timing of their use. On the other hand, drug-induced AIH, like hepatitis, also exists and is clinically important because it is often difficult to differentiate from idiopathic AIH. A solid understanding of the pathogenesis of both AIH and DILI is essential for clinicians. This article provides an overview of AIH and DILI in Japan, including the latest findings.<\/jats:p>","DOI":"10.3390\/jcm14134514","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T05:53:13Z","timestamp":1750917193000},"page":"4514","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autoimmune Hepatitis and Drug-Induced Liver Injury in Japan"],"prefix":"10.3390","volume":"14","author":[{"given":"Hiroki","family":"Nishikawa","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5527-6555","authenticated-orcid":false,"given":"Soo Ki","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kobe Asahi Hospital, Kobe 653-8501, Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2915-7875","authenticated-orcid":false,"given":"Akira","family":"Asai","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/hepr.13342","article-title":"Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan","volume":"49","author":"Tanaka","year":"2019","journal-title":"Hepatol. Res."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sirbe, C., Simu, G., Szabo, I., Grama, A., and Pop, T.L. (2021). Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413578"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4254\/wjh.v16.i2.186","article-title":"Recent advances in the diagnosis of drug-induced liver injury","volume":"16","author":"Ahmed","year":"2024","journal-title":"World J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jhep.2023.04.033","article-title":"Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report","volume":"79","author":"Andrade","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2023.06.002","article-title":"Autoimmune Hepatitis: Epidemiology, Subtypes, and Presentation","volume":"28","author":"Shiffman","year":"2024","journal-title":"Clin. Liver Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/liv.15155","article-title":"Epidemiology and surveillance of autoimmune hepatitis in Asia","volume":"42","author":"Katsumi","year":"2022","journal-title":"Liver Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00535-016-1267-0","article-title":"Autoimmune hepatitis in Japan: Trends in a nationwide survey","volume":"52","author":"Takahashi","year":"2017","journal-title":"J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s12072-024-10714-1","article-title":"Acute presentation of autoimmune hepatitis\u2014From acute hepatitis to ALF and ACLF","volume":"18","author":"Tanaka","year":"2024","journal-title":"Hepatol. Int."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Takahashi, A., Ohira, H., Abe, K., Zeniya, M., Abe, M., Arinaga-Hino, T., Torimura, T., Yoshizawa, K., Takaki, A., and Kang, J.H. (2020). Increasing incidence of acute autoimmune hepatitis: A nationwide survey in Japan. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-71296-0"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3748\/wjg.v28.i24.2654","article-title":"Drug-induced autoimmune hepatitis: A minireview","volume":"28","author":"Tan","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9437043","DOI":"10.1155\/2019\/9437043","article-title":"Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies","volume":"2019","author":"Sucher","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/imm.13665","article-title":"Autoantigen-selected B cells are bystanders in spontaneous T cell-driven experimental autoimmune hepatitis","volume":"170","author":"Preti","year":"2023","journal-title":"Immunology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep4.1326","article-title":"Interleukin-33\/ST2-mediated inflammation plays a critical role in the pathogenesis and severity of type I autoimmune hepatitis","volume":"3","author":"Abe","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e3194","DOI":"10.1097\/MD.0000000000003194","article-title":"B-Cell Activating Factor Belonging to the Tumor Necrosis Factor Family and Interferon-\u03b3-Inducible Protein-10 in Autoimmune Hepatitis","volume":"95","author":"Nishikawa","year":"2016","journal-title":"Medicine"},{"key":"ref_15","first-page":"124","article-title":"Autoimmune Hepatitis: Serum Autoantibodies in Clinical Practice","volume":"63","author":"Vergani","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/MEG.0000000000002747","article-title":"The frequency and clinical significance of antibodies to soluble liver antigen\/liver pancreas in autoimmune hepatitis: A prospective single-center study","volume":"36","author":"Kina","year":"2024","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8446170","DOI":"10.1155\/2022\/8446170","article-title":"Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"2022","author":"Luo","year":"2022","journal-title":"Dis. Markers"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000454879","article-title":"Similarities and Differences in Autoimmune Hepatitis Epidemiology between East and West: Autoimmune Hepatitis in East Asia, Southeast Asia, and South Asia","volume":"1","author":"Enomoto","year":"2017","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2024.12.041","article-title":"Update in clinical science: Autoimmune hepatitis","volume":"82","author":"Heneghan","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/hep.22825","article-title":"Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients","volume":"49","author":"Muratori","year":"2009","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jhep.2010.06.032","article-title":"Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients","volume":"54","author":"Qiu","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.dld.2009.06.013","article-title":"Clinical features of autoimmune hepatitis diagnosed based on simplified criteria of the International Autoimmune Hepatitis Group","volume":"42","author":"Miyake","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3748\/wjg.v25.i19.2308","article-title":"Autoimmune hepatitis and IgG4-related disease","volume":"25","author":"Minaga","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jhep.2021.06.035","article-title":"Acute-on-chronic liver failure: A complex clinical entity in patients with autoimmune hepatitis","volume":"75","author":"Granito","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/hepr.13776","article-title":"Clinical practice guidelines for autoimmune hepatitis","volume":"52","author":"Ohira","year":"2022","journal-title":"Hepatol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Miao, Q., Yan, L., Zhou, Y., Li, Y., Zou, Y., Wang, L., Bai, Y., and Zhang, J. (2021). Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in southwest china patients with autoimmune hepatitis. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-87095-0"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.4254\/wjh.v13.i11.1642","article-title":"Health-related quality of life in autoimmune hepatitis","volume":"13","author":"Snijders","year":"2021","journal-title":"World J. Hepatol."},{"key":"ref_31","first-page":"5153","article-title":"Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis","volume":"8","author":"Lin","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Liu, Q., Tian, H., Kang, Y., Tian, Y., Li, L., Kang, X., Yang, H., Wang, Y., Tian, J., and Zhang, F. (2021). Probiotics alleviate autoimmune hepatitis in mice through modulation of gut microbiota and intestinal permeability. J. Nutr. Biochem., 98.","DOI":"10.1016\/j.jnutbio.2021.108863"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00535-018-1486-7","article-title":"NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: A multicenter study","volume":"53","author":"Kakuta","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1080\/00365521.2021.1953127","article-title":"Systematic review with meta-analysis: Autoimmune hepatitis in pregnancy","volume":"56","author":"Eslick","year":"2021","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/hep.32410","article-title":"Autoimmune hepatitis in pregnancy: Pearls and pitfalls","volume":"76","author":"Chung","year":"2022","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11894-015-0484-7","article-title":"Management of Difficult Cases of Autoimmune Hepatitis","volume":"18","author":"Lammert","year":"2016","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4254\/wjh.v9.i1.57","article-title":"Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis","volume":"9","author":"Torisu","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/hep.26578","article-title":"AASLD clinical practice guidelines: A critical review of scientific evidence and evolving recommendations","volume":"58","author":"Koh","year":"2013","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2015). EASL Clinical Practice Guidelines: Autoimmune hepatitis. J. Hepatol., 63, 971\u20131004.","DOI":"10.1016\/j.jhep.2015.06.030"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2012.09.009","article-title":"Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission","volume":"58","author":"Verwer","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1572-0241.2007.01153.x","article-title":"Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse","volume":"102","author":"Carpenter","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00535-021-01788-x","article-title":"Evidence-based clinical practice guidelines for Liver Cirrhosis 2020","volume":"56","author":"Yoshiji","year":"2021","journal-title":"J. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/apt.13894","article-title":"Systematic review: Recurrent autoimmune liver diseases after liver transplantation","volume":"45","author":"Bhanji","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jhep.2022.01.022","article-title":"Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation","volume":"77","author":"Ronca","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jhep.2021.02.006","article-title":"Primary biliary cholangitis associated with SARS-CoV-2 infection","volume":"74","author":"Bartoli","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/BOR.0000000000000776","article-title":"COVID-19 and autoimmune diseases","volume":"33","author":"Lui","year":"2021","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jhep.2021.05.038","article-title":"Autoimmune hepatitis following SARS-CoV-2 vaccine: May not be a casuality","volume":"75","author":"Rocco","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ajh.26132","article-title":"Thrombocytopenia following pfizer and moderna SARS-CoV-2 vaccination","volume":"96","author":"Lee","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zheng, H., Zhang, T., Xu, Y., Lu, X., and Sang, X. (2022). Autoimmune hepatitis after COVID-19 vaccination. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1035073"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3892\/mmr.2025.13471","article-title":"Underlying mechanisms and treatment of acetaminophen-induced liver injury (Review)","volume":"31","author":"Li","year":"2025","journal-title":"Mol. Med. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Iorga, A., Dara, L., and Kaplowitz, N. (2017). Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18051018"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","article-title":"Drug-Induced Hypersensitivity Syndrome (DIHS)\/Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis","volume":"10","author":"Hama","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hep.32327","article-title":"A revised electronic version of RUCAM for the diagnosis of DILI","volume":"76","author":"Hayashi","year":"2022","journal-title":"Hepatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e0235","DOI":"10.1097\/HC9.0000000000000235","article-title":"Validation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients","volume":"8","author":"Zhao","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/bs.apha.2019.02.001","article-title":"Biomarkers of drug-induced liver injury","volume":"85","author":"McGill","year":"2019","journal-title":"Adv. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Kwon, D., Choi, G., Park, S.A., Cho, S., Cho, S., and Ko, S. (2022). Liver Acinus Dynamic Chip for Assessment of Drug-Induced Zonal Hepatotoxicity. Biosensors, 12.","DOI":"10.3390\/bios12070445"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs\u2014I. A novel method based on the con clusions of international consensus meetings: Application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/hepr.14046","article-title":"RECAM-J 2023-Validation and development of the Japanese version of RECAM for the diagnosis of drug-induced liver injury","volume":"54","author":"Tanaka","year":"2024","journal-title":"Hepatol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.26709","article-title":"Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations","volume":"59","author":"Kleiner","year":"2014","journal-title":"Hepatology"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Pascual, E., Rienda, I., Perez-Rojas, J., Rapisarda, A., Garcia-Llorens, G., Jover, R., and Castell, J.V. (2024). Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105203"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0034-1375963","article-title":"Drug-induced nodular regenerative hyperplasia","volume":"34","author":"Ghabril","year":"2014","journal-title":"Semin. Liver Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3748\/wjg.v28.i14.1384","article-title":"Hepatocellular adenoma: Where are we now?","volume":"28","author":"Wang","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/hepr.13288","article-title":"Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan","volume":"49","author":"Aiso","year":"2019","journal-title":"Hepatol. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"102514","DOI":"10.1016\/j.jaut.2020.102514","article-title":"Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development","volume":"114","author":"Regev","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.mcna.2022.12.008","article-title":"Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors","volume":"107","author":"Bessone","year":"2023","journal-title":"Med. Clin. N. Am."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8436 Patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res. Treat."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/HEP.0000000000000045","article-title":"Checkpoint inhibitor hepatotoxicity: Pathogenesis and manage ment","volume":"79","author":"Cunningham","year":"2024","journal-title":"Hepatology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: A systematic review of clinical features and management","volume":"33","author":"Pi","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2019). EASL Clinical Practice Guidelines: Drug-induced liver injury. J. Hepatol., 70, 1222\u20131261.","DOI":"10.1016\/j.jhep.2019.02.014"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0016-5085(93)90853-5","article-title":"Cytochromes P-450 in human hepatocyte plasma membrane; recognition by several autoantibodies","volume":"104","author":"Loeper","year":"1993","journal-title":"Gastroenterology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0168-8278(97)82329-X","article-title":"Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis","volume":"26","author":"Robin","year":"1997","journal-title":"J. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/hep4.1959","article-title":"Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports","volume":"6","author":"Andrade","year":"2022","journal-title":"Hepatol. Commun."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4514\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:58:45Z","timestamp":1760032725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":74,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["jcm14134514"],"URL":"https:\/\/doi.org\/10.3390\/jcm14134514","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,6,25]]}}}